Ecuador has approved the use of Chinese vaccine company CanSino Biologics Inc's (HKG: 6185) COVID-19 vaccine, Reuters news agency reported on Wednesday.
The President of Ecuador, Guillermo Lasso, had announced the purchase of six million doses of the CanSino shot, with the aim of vaccinating nine million people in the first 100 days of his government.
The Ecuador government is also negotiating the purchase of 18 million doses of Russia's Sputnik V COVID-19 vaccine and is asking pharmaceutical companies to speed up the delivery of doses they had previously agreed to provide.
According to Ecuador's health ministry, so far the country has vaccinated over a million people.
Ecuador expects to receive another 814,000 COVID-19 vaccines this week as part of deals already negotiated with laboratories, Reuters added.
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine